Invention Grant
US09012448B2 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
有权
1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
![1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors](/docs/US/2015-04-21/US09012448B2/abs.jpg.600x600.jpg)
- Patent Title: 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
- Patent Title (中): 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
-
Application No.: US13884149Application Date: 2011-11-08
-
Publication No.: US09012448B2Publication Date: 2015-04-21
- Inventor: José Maria Cid-Núñez , Andrés Avelino Trabanco-Suárez , Juan Antonio Vega Ramiro , Daniel Oehlrich , Gary John Tresadern , Gregor James MacDonald
- Applicant: José Maria Cid-Núñez , Andrés Avelino Trabanco-Suárez , Juan Antonio Vega Ramiro , Daniel Oehlrich , Gary John Tresadern , Gregor James MacDonald
- Applicant Address: US NJ Titusville
- Assignee: Janssen Pharmaceuticals, Inc.
- Current Assignee: Janssen Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Titusville
- Agent Hal B. Woodrow
- Priority: EP10190327 20101108
- International Application: PCT/EP2011/069641 WO 20111108
- International Announcement: WO2012/062751 WO 20120518
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61K45/06 ; C07D471/04 ; A61K9/00 ; A61K9/06 ; A61K9/10 ; A61K9/20 ; A61K31/542
![1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors](/abs-image/US/2015/04/21/US09012448B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
Public/Granted literature
Information query
IPC分类:
